Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
|Study Design:||Time Perspective: Prospective|
|Official Title:||Treatment Strategies for Myeloproliferative Neoplasms by Targeting the Tumor Suppressor P53|
- Stem cell function [ Time Frame: at one time study visit ] [ Designated as safety issue: No ]Assess the effects of RG7112 on MPN HSC/HPC p53 levels and study how it affects MPN stem cell function.
- CD34+ cells assays [ Time Frame: at one time study visit ] [ Designated as safety issue: No ]Assess the effects of a combination of low doses of IFNα and RG7112 on MPN HSC/HPC. After treatment with RG7112 and IFNα at the various doses, p53, MDM2, MDMX, phosphor-p38, and phosphor-STAT1 levels in MPN CD34+ cells will be measured using monoclonal antibody staining and flow cytometric and immunofluorescence analyses.
Biospecimen Retention: Samples Without DNA
|Study Start Date:||August 2012|
|Estimated Study Completion Date:||January 2017|
|Estimated Primary Completion Date:||January 2017 (Final data collection date for primary outcome measure)|
PV or ET
subject who has polycythemia vera or essential thrombocythemia
Procedure: Blood specimen
4 green top tube 40 cc of blood draw
Specific Aim 1: Assess the effects of RG7112 on MPN HSC/HPC p53 levels and study how it affects MPN stem cell function.
Specific Aim 2. Assess the effects of a combination of low doses of IFNα and RG7112 on MPN HSC/HPC.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01970930
|Contact: Jill Kleczko, MPAemail@example.com|
|Contact: Ronald Hoffman, MDfirstname.lastname@example.org|
|United States, New York|
|Icahn School of Medicine at Mount Sinai||Recruiting|
|New York, New York, United States, 10029|
|Principal Investigator: Ronald Hoffman, MD|
|Principal Investigator:||Ronald Hoffman, MD||Icahn School of Medicine at Mount Sinai|